



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of
Borcherding et al.

Application No.: **10/677,683**

Filed: **October 2, 2003**

Title: **ACYL AND SULFONYL DERIVATIVES OF
6,9-DISUBSTITUTED 2-(TRANS-1,4-
DIAMINOCYCLOHEXYL)-PURINES AND
THEIR USE AS ANTIPIROLIFERATIVE
AGENTS**

Examiner: **BERCH, Mark L.**
Art Unit: **1624**

Certificate of Mailing or Transmission
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.
Date of Deposit Oct 21, 2006
Printed Name of Person Signing Certificate Mrs. Caught
Signature Delia Caught

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED**

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. **18-1982** in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

Respectfully submitted,


George S. Jones, Reg. No. 38,508
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3776
Telefax (908) 231-2626

sanofi-aventis Docket No. USA3960 US CNT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Borchering et al.

Application No.: **10/677,683**

Filed: **October 2, 2003**

Title: **ACYL AND SULFONYL DERIVATIVES
OF 6,9-DISUBSTITUTED 2-(TRANS-
1,4-DIAMINOCYCLOHEXYL)-
PURINES AND THEIR USE AS
ANTIPROLIFERATIVE AGENTS**

Examiner: **BERCH, Mark L.**

Art Unit: **1624**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

Feb 27, 2006
Date of Deposit

Signature

Dicks Conheen

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

(b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

(1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;


(2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or

(3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.


The items listed with an asterisk on the attached PTO-1449 (modified) have been previously submitted by the examiner or the applicant in related applications of this series.

Therefore, a copy of the reference(s) are not enclosed with this Information Disclosure Statement.

Respectfully submitted,


George S. Jones
Reg No. 38,508
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3776
Telefax (908) 231-2626
sanofi-aventis Docket No. USA3960 US CNT



Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shee

1

of

?

Complete if Known

OFFICE Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/677,683</td> </tr> <tr> <td>Filing Date</td> <td>October 2, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>BORCHERDING et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>1624</td> </tr> <tr> <td>Examiner Name</td> <td>BERCH, Mark L.</td> </tr> <tr> <td>Attorney Docket Number</td> <td>USA3960 US CNT</td> </tr> </table>	Application Number	10/677,683	Filing Date	October 2, 2003	First Named Inventor	BORCHERDING et al.	Group Art Unit	1624	Examiner Name	BERCH, Mark L.	Attorney Docket Number	USA3960 US CNT
Application Number	10/677,683												
Filing Date	October 2, 2003												
First Named Inventor	BORCHERDING et al.												
Group Art Unit	1624												
Examiner Name	BERCH, Mark L.												
Attorney Docket Number	USA3960 US CNT												
Sheet	1	of	2										

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴			
*	EP	0545413			07-12-2000	
*	WO	WO 00/44750			08-03-2000	
*	WO	WO 94/17090			08-04-1994	
*	WO	WO 96/02543			02-01-1996	
*	WO	WO 97/16452			05-09-1997	
*	WO	WO 97/20,842			06-12-1997	
*	WO	WO 98/05335			02-12-1998	
*	WO	WO 99/07705			02-18-1999	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Approved for use through 10/31/2001 GPO: 2001-000-0007-0001
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/677,683
		Filing Date	October 2, 2003
		First Named Inventor	BORCHERDING et al.
		Group Art Unit	1624
		Examiner Name	BERCH, Mark L.
Sheet	2	of	2
		Attorney Docket Number	USA3960 US CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		*KATH John C, Patent Focus: Inhibitors of Tumour Cell Growth, J.C., Oncologic, Endocrine & Metabolic, Exp. Opin. Ther. Patents (2000), 10(6):803:818	
		*MYERS Michael R et al., Inhibitors of Tyrosine Kinases Involved in Inflammation and Autoimmune Disease, Current Pharmaceuticals Design, 1997, Vol. 3, No. 5, pages 473-502	
		*PARK David S et al., G1/S Cell Cycle Blockers and Inhibitors of Cyclin-Dependent Kinases Suppress Camptothecin-Induced Neuronal Apoptosis, J. of Neuroscience, 17(4):1256-1270 (1997)	
		*PARK David S et al., Inhibitors of Cyclin-Dependent Kinases Promote Survival of Post-mitotic Neuronally Differentiated PC12 Cells and Sympathetic Neurons, J. of Biological Chemistry, Vol. 271, No. 14:8161-8169 (1996)	
		*ROSANIA Gustavo R et al., Targeting Hyperproliferative Disorders with Cyclin Dependent Kinase Inhibitors, Publication Exp. Opin. Ther. Patents (2000) 10(2):215-230	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.